concentra alumis - Search News

Acelyrin, Concentra and Biosciences

Concentra Offers to Buy Acelyrin, Endangering Proposed Merger With Alumis

Acelyrin earlier this month agreed to an all-stock merger with fellow immune player Alumis, with their combined cash tiding the combined company over until 2027.

Hosted on MSN · 2d

Acelyrin jumps 11% on acquisition offer from Concentra Biosciences

Acelyrin (NASDAQ:SLRN) received an unsolicited acquisition offer from Concentra Biosciences, controlled by Tang Capital Partners. The proposal includes a cash payment of $3.00 per share, along with a contingent value right (CVR) that entitles shareholders to 80% of the net proceeds from any future out-licensing or sale of Acelyrin's development

Business Insider · 2d

ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences

On February 6, 2025, ACELYRIN announced an agreement to merge with Alumis Inc. (Nasdaq: ALMS) in an all-stock transaction. The transaction is expected to close in the second quarter of 2025, subject to approval by the stockholders of both companies and satisfaction of other customary closing conditions.

MarketWatch · 1d

Acelyrin Stock Jumps on Concentra Acquisition Interest

Shares of Acelyrin climbed after the company said it has received an unsolicited indication of interest from Concentra Biosciences for an acquisition at $3 a share. The stock was up 14% at $2.48 in premarket trading. Shares had fallen 31% year to date when the market closed Thursday.

FierceBiotech1d

Concentra curveball offer throws Acelyrin merger with Alumis into doubt

As part of an agreement announced two weeks ago, eye-disease-focused Acelyrin was due to be absorbed into immune-mediated ...

The Business Journals2d

Activist investor threatens Peninsula drug maker's merger plans

The drama introduces a potential choice for Acelyrin shareholders: cash now in a deal with Concentra or a potentially bigger return from the all-stock merger with Alumis. Two weeks after Alumis ...

ENDPOINTS NEWS1d

Kevin Tang's Concentra tries to disrupt proposed Acelyrin-Alumis merger

Tang Capital's Concentra Biosciences offers to buy Acelyrin for $3/share, challenging planned Alumis merger. Concentra would ...

Investing1d

ACELYRIN shares surge on buyout interest

The interest from Concentra Biosciences includes an offer to purchase all outstanding shares of ACELYRIN at $3.00 each, plus a contingent value right tied to 80% of net proceeds from potential future ...

Acelyrin confirms unsolicited indication of interest from Concentra Biosciences

Acelyrin (SLRN) “confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results